CLINICAL COLLABORATION AGREEMENTClinical Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • New York
This CLINICAL COLLABORATION AGREEMENT (this “Agreement”) is entered into as of June 23, 2023 (the “Effective Date”), by and between ArriVent BioPharma Inc., having an address at 18 Campus Blvd., Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”), and Beijing InnoCare Pharma Tech Co., Ltd., having an address at Building 8, No. 8 Life Science Park Road, ZGC Life Science Park, Changping District, Beijing, China 102206 (“InnoCare”). ArriVent and InnoCare are each referred to herein individually as “Party” and collectively as “Parties”.
EX-10.12 12 filename12.htm [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as...Clinical Collaboration Agreement • May 5th, 2020 • New York
This CLINICAL COLLABORATION AGREEMENT (the “Agreement”) is entered into and made effective as of October 16, 2012 (the “Effective Date”), by and among Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA (“Portola”), Bristol-Myers Squibb Company, a corporation organized and existing under the laws of Delaware, having its principal place of business at 345 Park Avenue, New York, NY 10154 (“BMS”), and Pfizer Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 235 East 42nd Street, New York, New York 1017 (“Pfizer”). Each of Portola, BMS and Pfizer are referred to individually as a “Party” and collectively as the “Parties.”
CLINICAL COLLABORATION AGREEMENT BY AND BETWEEN HUMANIGEN, INC. AND KITE PHARMA, INC.Clinical Collaboration Agreement • August 13th, 2019 • Humanigen, Inc • Pharmaceutical preparations • California
This Clinical Collaboration Agreement (“Agreement”) is made and entered into, effective as of May 30, 2019 (“Effective Date”), by and between Humanigen, Inc., a Delaware corporation, having a principal place of business at 533 Airport Boulevard, Suite 400, Burlingame, CA 94010 (“Humanigen”) and Kite Pharma, Inc., a Delaware corporation, having a place of business at 2400 Broadway, Santa Monica, CA 90404 (“Kite”). Humanigen and Kite are each referred to herein individually as a “Party” and collectively as the “Parties.”
4Living Biotech and Sanofi enter into a collaboration agreement to demonstrate potential clinical efficacy of Mozobil® as a treatment for acute and chronic complications of COVID-19Clinical Collaboration Agreement • November 22nd, 2021
This trial leverages on recent studies that have shown that the expression of the CXCR4 receptor by neutrophils and lymphocytes correlates with the severity and morbidity of COVID- 19 patients. 4LB and its partners have demonstrated the efficacy of Mozobil® in blocking this receptor to improve the pulmonary pathophysiology associated with respiratory viral infection.
Institutional Conflict of Interest Management and Monitoring Plan: Cyclacel LimitedClinical Collaboration Agreement • November 16th, 2018
The University of Texas MD Anderson (MD Anderson) and Cyclacel Limited (Cyclacel) are parties to a Clinical Collaboration Agreement (Agreement) pursuant to which MD Anderson will conduct four clinical research studies using various drugs, including Cyclacel drugs (Studies).
CLINICAL COLLABORATION AGREEMENTClinical Collaboration Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Clinical Collaboration Agreement (this “Agreement”), made as of August 16, 2018 (the “Effective Date”), is by and between SpringWorks Subsidiary 3, PBC, a public benefit corporation organized under the laws of Delaware (“SpringWorks”), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having its principal address at Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, Cayman Islands KY1-1108 (“BeiGene”). BeiGene and SpringWorks are each referred to herein as a “Party” and are collectively referred to as the “Parties”.
Telix Pharmaceuticals and Radboud University Medical Centre Conclude Clinical Collaboration AgreementClinical Collaboration Agreement • March 15th, 2018
Melbourne (Australia) and Nijmegen (Netherlands) – 15 February 2018. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today announced a clinical collaboration with Radboud University Medical Center (“Radboudumc”).
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the...Clinical Collaboration Agreement • November 13th, 2018 • Cyclacel Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
This Clinical Collaboration Agreement (“Agreement”), effective as of the 21 day of August, 2018 (“Effective Date”), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”) and Cyclacel Limited, with a place of business located at 1 James Lindsay Place, Dundee, Scotland, DD1 5JJ, United Kingdom, (“Cyclacel”) (MD Anderson and Cyclacel each a “Party,” and collectively, the “Parties”).
